-
公开(公告)号:US09365522B2
公开(公告)日:2016-06-14
申请号:US14633936
申请日:2015-02-27
申请人: AMGEN INC. , TEIJIN PHARMA LIMITED
发明人: Hilary Plake Beck , Shon Keith Booker , Howard Bregman , Victor J. Cee , Nagasree Chakka , Timothy D. Cushing , Oleg Epstein , Brian M. Fox , Stephanie Geuns-Meyer , Xiaolin Hao , Kenta Hibiya , Jun Hirata , Zihao Hua , Jason Human , Shinji Kakuda , Patricia Lopez , Ryota Nakajima , Kazuhisa Okada , Steven H. Olson , Hiroyuki Oono , Lewis D. Pennington , Kosuke Sasaki , Keiko Shimada , Youngsook Shin , Ryan D. White , Ryan P. Wurz , Shuyan Yi , Xiao Mei Zheng
IPC分类号: C07D231/14 , C07D403/12 , C07D401/14 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/14 , C07D493/08 , C07D413/12 , A61K31/4155 , A61K31/44 , A61K31/4427 , A61K31/422
CPC分类号: C07D231/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/14 , C07D493/08
摘要: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
摘要翻译: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物,该化合物在治疗或预防自身免疫疾病,炎性疾病,代谢疾病或癌症疾病中的用途。
-
公开(公告)号:US20150266824A1
公开(公告)日:2015-09-24
申请号:US14633936
申请日:2015-02-27
申请人: AMGEN INC. , Teijin Pharma Limited
发明人: Hilary Plake Beck , Shon Keith Booker , Howard Bregman , Victor J. Cee , Nagasree Chakka , Timothy D. Cushing , Oleg Epstein , Brian M. Fox , Stephanie Geuns-Meyer , Xiaolin Hao , Kenta Hibiya , Jun Kirata , Zihao Hua , Jason Human , Shinji Kakuda , Patricia Lopez , Ryota Nakajima , Kazuhisa Okada , Steven H. Olson , Hiroyuki Oono , Lewis D. Pennington , Kosuke Sasaki , Keiko Shimada , Youngsook Shin , Ryan D. White , Ryan P. Wurz , Shuyan Yi , Xiao Mei Zheng
IPC分类号: C07D231/14 , C07D409/12 , C07D413/12 , C07D405/14 , C07D401/14 , C07D493/08 , C07D401/12 , C07D403/12
CPC分类号: C07D231/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/14 , C07D493/08
摘要: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
摘要翻译: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物,该化合物在治疗或预防自身免疫疾病,炎性疾病,代谢疾病或癌症疾病中的用途。
-
公开(公告)号:US11096939B2
公开(公告)日:2021-08-24
申请号:US16428163
申请日:2019-05-31
申请人: Amgen Inc.
发明人: Shon Booker , John Gordon Allen , Brian Alan Lanman , Ryan Paul Wurz , Ning Chen , Victor J. Cee , Patricia Lopez , Aaron C. Siegmund , Michael D. Bartberger
IPC分类号: C07D471/04 , A61K31/497 , C07K16/28
摘要: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US11285135B2
公开(公告)日:2022-03-29
申请号:US16675121
申请日:2019-11-05
申请人: AMGEN INC.
发明人: Brian Alan Lanman , Victor J. Cee , Alexander J. Pickrell , Anthony B. Reed , Kevin C. Yang , David John Kopecky , Hui-Ling Wang , Patricia Lopez , Kate Ashton , Shon Booker , Christopher M. Tegley
IPC分类号: C07D417/04 , C07D417/14 , C07D513/04 , A61K31/428 , A61K31/496 , A61K31/519 , A61P35/00 , A61K31/5025 , A61K31/502 , A61K31/517 , C07D275/04 , C07D471/08 , C07D403/04 , C07D401/04 , C07D487/04 , C07D239/80 , C07D487/10 , C07D471/04
摘要: Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US11090304B2
公开(公告)日:2021-08-17
申请号:US16402538
申请日:2019-05-03
申请人: Amgen Inc.
发明人: John Gordon Allen , Jennifer Rebecca Allen , Ana Elena Minatti , Qiufen Xue , Ryan Paul Wurz , Christopher M. Tegley , Alexander J. Pickrell , Thomas T. Nguyen , Vu Van Ma , Patricia Lopez , Longbin Liu , David John Kopecky , Michael J. Frohn , Ning Chen , Jian Jeffrey Chen , Aaron C. Siegmund , Albert Amegadzie , Nuria A. Tamayo , Shon Booker , Clifford Goodman , Mary Walton , Nobuko Nishimura , Youngsook Shin , Jonathan D. Low , Victor J. Cee , Anthony B. Reed , Hui-Ling Wang , Brian Alan Lanman
IPC分类号: A61K31/517 , A61P35/00 , A61K31/4985 , A61K39/395 , C07D403/04 , C07D471/04
摘要: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US11053226B2
公开(公告)日:2021-07-06
申请号:US16687546
申请日:2019-11-18
申请人: Amgen Inc.
发明人: Youngsook Shin , Victor J. Cee , Christopher M. Tegley , Brian Alan Lanman , Ryan Paul Wurz , Kevin C. Yang , Vu Van Ma , Daniel Erlanson , Joon Won Jeong , Raymond V. Fucini , Jeffrey Iwig
IPC分类号: C07D403/14 , C07D401/14 , C07D403/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D498/04 , A61P35/00
摘要: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US10988485B2
公开(公告)日:2021-04-27
申请号:US16407889
申请日:2019-05-09
申请人: Amgen Inc.
发明人: Ana Elena Minatti , Jonathan Dante Low , Ryan Paul Wurz , Brian Alan Lanman , Victor J. Cee , Michael D. Bartberger , Margaret Chu-Moyer
IPC分类号: C07D513/04 , A61K45/06 , C07K16/28
摘要: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US10519146B2
公开(公告)日:2019-12-31
申请号:US15984855
申请日:2018-05-21
申请人: Amgen Inc.
发明人: Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen
IPC分类号: C07D471/04 , C07D487/04 , C07D403/04 , C07D401/04 , C07D475/00 , A61K31/496 , A61K31/519 , A61P35/00 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D239/80 , C07D401/14 , C07D237/34 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/517 , A61K31/502 , A61K31/5025 , A61K31/7068 , C07D275/04
摘要: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US11905281B2
公开(公告)日:2024-02-20
申请号:US17031607
申请日:2020-09-24
申请人: Amgen Inc.
发明人: Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen
IPC分类号: C07D471/04 , C07D213/82 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D487/04 , C07D401/04 , C07D239/80 , C07D401/14 , C07D237/34 , C07D403/04 , A61K31/496 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/519 , A61K31/502 , A61K31/517 , A61K31/5025 , A61P35/00 , A61K31/7068 , C07D275/04 , C07D475/00
CPC分类号: C07D417/04 , A61K31/416 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/7068 , A61K38/07 , A61P35/00 , C07D237/34 , C07D239/80 , C07D275/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D471/04 , C07D475/00 , C07D487/04 , C07D487/08 , C07D487/10 , C07D513/04
摘要: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
-
公开(公告)号:US11426404B2
公开(公告)日:2022-08-30
申请号:US15930606
申请日:2020-05-13
申请人: AMGEN INC.
IPC分类号: A61K31/505 , A61P35/00 , A61K9/00 , A61K31/53 , A61K31/5355 , A61K39/00
摘要: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
-
-
-
-
-
-
-
-